Fig. 1From: Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinomaFlowchart of the process of identifying patients with advanced hepatocellular carcinoma who received nivolumab or pembrolizumab after progression on sorafenib or lenvatinibBack to article page